Trial Profile
Phase I Study of Epigenetic Priming Using Azacitidine With Neoadjuvant Chemotherapy in Patients With Resectable Esophageal Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 Dec 2018
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Capecitabine; Epirubicin; Oxaliplatin
- Indications Oesophageal cancer
- Focus Adverse reactions
- Acronyms VEOX
- 10 Dec 2018 Status changed from active, no longer recruiting to completed.
- 30 Jan 2018 Planned End Date changed from 1 Nov 2017 to 1 Nov 2018.
- 23 Jan 2017 Planned End Date changed from 1 Jun 2013 to 1 Nov 2017.